AEterna Zentaris signed a development, commercialization and licensing agreement with Sanofi-Aventis for cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market. Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, is currently in Phase III development for BPH, a non-cancerous enlargement of the prostate. Under the terms of the agreement, AEterna Zentaris will receive an initial $30 million in upfront payments and is eligible to receive as much as $135 million i...